JP2761815B2 - Butyric acid bacteria solution - Google Patents
Butyric acid bacteria solutionInfo
- Publication number
- JP2761815B2 JP2761815B2 JP3169893A JP16989391A JP2761815B2 JP 2761815 B2 JP2761815 B2 JP 2761815B2 JP 3169893 A JP3169893 A JP 3169893A JP 16989391 A JP16989391 A JP 16989391A JP 2761815 B2 JP2761815 B2 JP 2761815B2
- Authority
- JP
- Japan
- Prior art keywords
- butyric acid
- acid bacterium
- spores
- acid bacteria
- germination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16H—GEARING
- F16H25/00—Gearings comprising primarily only cams, cam-followers and screw-and-nut mechanisms
- F16H25/18—Gearings comprising primarily only cams, cam-followers and screw-and-nut mechanisms for conveying or interconverting oscillating or reciprocating motions
- F16H25/20—Screw mechanisms
- F16H25/24—Elements essential to such mechanisms, e.g. screws, nuts
- F16H2025/249—Special materials or coatings for screws or nuts
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は、人又は動物の腸内菌叢
の異状による諸症状を改善するための、酪酸菌を含む液
剤に関し、さらに詳しくは、この液剤およびこれを用い
た懸濁剤、シロップ剤、リモナーデ剤等の内用液剤、な
らびにドリンク剤、清涼飲料水、液状食品、半流動状食
品、湿性食品（例えばアイスクリーム)、さらにこれらの
用時調製剤ならびに用時調製食品に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a solution containing butyric acid bacteria for improving various symptoms caused by abnormalities of the intestinal flora of humans or animals, and more particularly to this solution and a suspension using the same. Preparations, liquid preparations, liquid foods, semi-fluid foods, wet foods (eg ice cream), preparations for use and preparations for use at the time of use .
【０００２】[0002]
【従来の技術】酪酸菌は、従来より、整腸用医薬品とし
ては、錠剤、顆粒剤、散剤などの固形剤、また食品とし
ては、固形物として使用されてきた。しかし、消化器系
になんらかの異状が起こり、腹痛、下痢、腹鳴などの症
状が出現し、さらに悪心、嘔気、嘔吐、胃部不快感、食
欲不振、脱力感を呈する場合などに、無味乾燥な固形薬
品を服用することは容易ではない。特に小児への投与は
容易でなく、服みやすい剤型にするなどの配慮が望まれ
ている。2. Description of the Prior Art Butyric acid bacteria have been conventionally used as intestinal medicines as solids such as tablets, granules and powders, and as foods as solids. However, when there is any abnormality in the digestive system, symptoms such as abdominal pain, diarrhea, and wheezing, and nausea, nausea, vomiting, gastric discomfort, anorexia, weakness, etc. Taking solid medicines is not easy. In particular, it is not easy to administer to children, and it is desired to consider a dosage form that is easy to take.
【０００３】[0003]
【発明が解決しようとする課題】酪酸菌（Clostridium
butyricum)は分類学上、芽胞（内生胞子）を形成するグ
ラム陽性の偏性嫌気性桿菌であり、本菌の特徴は図１に
示す生活環をなしていることである。すなわち、酪酸菌
は温度、pH、栄養等の生育環境が整っていれば、栄養体
細胞として分裂増殖を行なう。この環境が悪化するに伴
い紡錐体細胞となり、やがて芽胞を形成してその代謝を
停止する。この芽胞は熱、乾燥、酸素、圧力等に対して
抵抗性が強く、製剤処理に十分に耐え、さらに低pH、胃
液中消化酵素等に対しても抵抗性があり、胃内で死滅す
ることなく腸内に到達し、発育増殖を起こしてその整腸
作用を発現する。[Problems to be solved by the invention] Butyric acid bacteria (Clostridium)
butyricum) is a taxonomically Gram-positive obligate anaerobic bacillus that forms spores (endospores). The feature of this bacterium is that it forms a life cycle as shown in FIG. That is, butyric acid bacteria divide and proliferate as vegetative cells if the growth environment such as temperature, pH, and nutrition is adjusted. As the environment worsens, the cells become spindle cells, which eventually form spores and stop their metabolism. These spores are highly resistant to heat, dryness, oxygen, pressure, etc., sufficiently tolerate drug treatment, and are also resistant to low pH, digestive enzymes in gastric juice, etc. Instead, it reaches the intestine, develops and proliferates, and expresses its intestinal action.
【０００４】一方、栄養体細胞は、上述の物理的化学的
諸因子に対しての抵抗性は芽胞よりも著しく弱く、製剤
処理あるいは生体内において、必ずしもその目的を達し
得ない。従って、酪酸菌製剤の投与菌形態は芽胞である
ことが望ましい。ところが、この芽胞は水分の存在によ
り容易に発芽の初期反応であるダークニングを経て栄養
体細胞となる。栄養体細胞は勿論、このダークニングを
起こした芽胞も酸素や熱等に対する感受性が高いことか
ら、水系においてこのダークニングを起こさないこと、
即ち水系において発芽させないことが必要であり、これ
が本発明の解決しようとする課題である。[0004] On the other hand, vegetative body cells are much weaker in resistance to the above-mentioned physical and chemical factors than spores, and cannot always achieve their purpose in pharmaceutical processing or in vivo. Therefore, it is desirable that the administration bacterial form of the butyric acid bacterium preparation is a spore. However, these spores easily become vegetative cells through darkening, which is the initial reaction of germination, due to the presence of water. Not only vegetative cells, but also spores that have caused this darkening are highly sensitive to oxygen, heat, etc., so that they do not cause this darkening in aqueous systems,
That is, it is necessary not to germinate in an aqueous system, and this is a problem to be solved by the present invention.
【０００５】[0005]
【課題を解決するための手段】本発明は、酪酸菌を含む
液にフェニルアラニンおよび／またはアスパラギンを
０．１％（重量）以上含有させることによりその芽胞細
胞が、水分の存在下においても発芽を起こさない液剤を
提供し、上記課題を解決した。SUMMARY OF THE INVENTION The present invention provides a solution containing butyric acid bacteria containing at least 0.1% (by weight) of phenylalanine and / or asparagine so that the spore cells can germinate even in the presence of water. A solution that does not wake up is provided, and the above problem is solved.
【０００６】すなわち、本発明の要旨は、酪酸菌を主成
分とし、フェニルアラニンおよび／またはアスパラギン
を０．１％以上含むことを特徴とする酪酸菌の液剤にあ
る。That is, the gist of the present invention is a solution of a butyric acid bacterium characterized by containing butyric acid bacterium as a main component and containing 0.1% or more of phenylalanine and / or asparagine.
【０００７】本発明で用いることができる酪酸菌は、例
えばClostridium butyricum NIP １００６（微工研菌寄
第１１８６８号）、Clostridium butyricum NIP １０１
５（微工研菌寄第１１８６９号）、Clostridium butyri
cum NIP １０１７（微工研菌寄第１１８７０号）であ
り、とくにクロストリジウム・ブチリカム・ミヤイリ５
８８（微工研菌寄第２７８９号）が好ましい。[0007] Butyric acid bacteria which can be used in the present invention include, for example, Clostridium butyricum NIP 1006 (No. 11868) and Clostridium butyricum NIP 101.
5, Clostridium butyri
cum NIP 1017 (Micron Laboratories No. 11870), especially Clostridium butyricum Miyairi 5
No. 88 (Microtechnical Laboratory No. 2789) is preferred.
【０００８】本発明に関しては、pHの発芽に及ぼす影響
も調べた。まず栄養豊富な GAM培地のpHを４．０，６．
０，６．９にそれぞれ調製し、これに芽胞を懸濁、３７
℃下、６０分間、ダークニングを観察した。その結果、
表−１に示すようにpH４．０ではダークニングは認めら
れず、pH６．０，６．９と、pHの上昇に伴ってダークニ
ングが顕著となった。また、 GAM培地において芽胞を接
種し、３７℃以下、２４時間放置するとpH６．０，６．
９の場合は発芽増殖するが、pH４．０の場合は変化が認
められなかった。これらの観察結果からみて、pH値は２
〜５が好ましく、とくにpH４〜５が好ましい。With respect to the present invention, the effect of pH on germination was also investigated. First, adjust the pH of the nutrient-rich GAM medium to 4.0,6.
0, 6.9, and spores were suspended therein.
Darkening was observed at 60 ° C. for 60 minutes. as a result,
As shown in Table 1, no darkening was observed at pH 4.0, and the pH became 6.0 and 6.9. When spores are inoculated in a GAM medium and left at 37 ° C. or lower for 24 hours, pH 6.0, 6.
In the case of 9, germination and growth occurred, but in the case of pH 4.0, no change was observed. From these observations, the pH value was 2
-5 is preferable, and pH 4-5 is particularly preferable.
【０００９】[0009]
【表１】 [Table 1]
【００１０】酪酸菌の液剤には、通常、飲み易くするた
め、あるいはおいしさを演出するため、甘味料など糖質
の添加剤が用いられるので、酪酸菌の１種であるクロス
トリジウム・ブチリカム・ミヤイリ５８８を被検菌と
し、表−２のMPBS培地を用い、先ず各種糖質が発芽に及
ぼす影響を観察した。各種糖類をそれぞれ０．１％の濃
度に加えた場合のダークニングを、分光光度計におい
て、３７℃下、その吸光度（６００ｎｍ）を経時的に測
定することによって観察した。その結果、第２図に示し
たように単糖であるグルコースが最も発芽を促進するこ
とが明らかとなった。そこで次に、このグルコースをMP
BS培地に添加し、この発芽し易い栄養条件（培地）にお
いて、すべてのアミノ酸の発芽抑制能について検討し
た。その結果、アミノ酸無添加のコントロールは顕著に
吸光度の低下、即ちダーニングが起こるが、グリシン、
アラニン、アスパラギン、フェニルアラニン、セリンを
添加した場合は、ダーニングが起こらなかった。一方、
ロイシン、イソロイシン、バリンが逆に発芽を加速し
た。[0010] Usually, clostridium butyricum miyairi, a kind of butyric acid bacterium, is used as a solution of butyric acid bacterium, because sugar additives such as sweeteners are used to make it easy to drink or produce a delicious taste. 588 was used as a test bacterium, and the effects of various carbohydrates on germination were first observed using the MPBS medium shown in Table 2. Darkening when various sugars were added to a concentration of 0.1%, respectively, was observed by measuring the absorbance (600 nm) of the spectrophotometer at 37 ° C. over time. As a result, it was revealed that glucose, which is a monosaccharide, promotes germination most, as shown in FIG. Then, next, this glucose is MP
Under the nutrient condition (medium) which was added to the BS medium and germinated easily, the ability of all amino acids to suppress germination was examined. As a result, the control with no amino acid added markedly decreases the absorbance, that is, darning occurs, but glycine,
Darning did not occur when alanine, asparagine, phenylalanine and serine were added. on the other hand,
Leucine, isoleucine and valine accelerated germination.
【００１１】[0011]
【表２】 [Table 2]
【００１２】以上の検討で、糖類ではグルコース、アミ
ノ酸類ではロイシン、イソロイシン、バリンが発芽を促
進することが明らかとなった。そこで今度はＭＰＢＳ培
地にグルコースとロイシンを添加した培地において、発
芽抑制能を有するグリシン、アラニン、アスパラギン、
フェニルアラニン、セリンの発芽に及ぼす影響を経時的
に詳細に観察した。その結果、グリシン、アラニン、セ
リンでは僅かながらダーニングが観察されたが、フェニ
ルアラニン（０．１％）とアスパラギン（０．１％）が
ダークニングを完全に抑止した。From the above studies, it was revealed that glucose promoted germination by saccharides and leucine, isoleucine and valine by amino acids. Therefore, this time, in a medium in which glucose and leucine are added to an MPBS medium, glycine, alanine, asparagine,
The effects of phenylalanine and serine on germination were observed over time in detail. As a result, slight darning was observed in glycine, alanine and serine, but phenylalanine (0.1%) and asparagine (0.1%) completely suppressed darkening.
【００１３】一方、当酪酸菌の発芽に及ぼす各種ビタミ
ンの影響をグルコース添加MPBS培地で観察したところ、
ビタミン９種はいずれも発芽には影響しないことが明ら
かとなった。On the other hand, when the effects of various vitamins on the germination of this butyric acid bacterium were observed in an MPBS medium containing glucose,
It was found that none of the nine vitamins affected germination.
【００１４】また発芽に及ぼす、温度の影響についても
検討した。グルコース添加MPBS培地に酪酸菌芽胞を懸濁
し、４℃もしくは３７℃に２４時間放置し、発芽を位相
差顕微鏡によって観察した。その結果、３７℃下の酪酸
菌は光沢のある完全芽胞がほとんど見られなかったのに
対し、４℃下の酪酸菌には変化は認められなかった。更
に栄養豊富な GAM寒天培地上における芽胞の安定性につ
いて観察した。芽胞を当平板に塗抹し、４℃あるいは３
７℃において２４時間放置後、GasPak法により培養し、
芽胞の生残率を求めた。表−３に示したように、栄養源
が豊富な環境において３７℃に放置した場合には、芽胞
の生残率が４．２％と極めて低いのに対して、４℃に放
置した場合には、芽胞生残率の低下が認められなかっ
た。これらのことはたとえ栄養が豊富であっても、４℃
では芽胞は安定であることを示している。The effect of temperature on germination was also examined. Butyric acid spores were suspended in an MPBS medium supplemented with glucose, left at 4 ° C. or 37 ° C. for 24 hours, and germination was observed by a phase contrast microscope. As a result, almost no glossy complete spores were observed in the butyric acid bacteria at 37 ° C, whereas no change was observed in the butyric acid bacteria at 4 ° C. Furthermore, the stability of spores on nutrient-rich GAM agar medium was observed. Spores are smeared on this plate, 4 ℃ or 3
After standing at 7 ° C for 24 hours, the cells were cultured by the GasPak method,
The survival rate of the spores was determined. As shown in Table 3, when left at 37 ° C in an environment rich in nutrients, the survival rate of spores was extremely low at 4.2%, whereas when left at 4 ° C. Showed no decrease in spore survival rate. These things, even if rich in nutrients,
Shows that the spores are stable.
【００１５】したがって、本発明の液剤は、４℃前後で
保存しておくことがのぞましい。Therefore, it is preferable that the liquid preparation of the present invention be stored at about 4 ° C.
【００１６】[0016]
【表３】 以上の実験結果より、酪酸菌芽胞の液中での安定は、
液pHを酸性にすること、または発芽抑制因子であるフ
ェニルアラニンもしくはアスパラギンを０．１％以上添
加することによって確保されることが明らかとなった。
添加量の上限は約２０％である。[Table 3] From the above experimental results, the stability of butyric acid spores in the liquid is
It has been clarified that the solution pH can be ensured by making the pH of the solution acidic or adding phenylalanine or asparagine which is a germination inhibitory factor in an amount of 0.1% or more.
The upper limit of the amount added is about 20%.
【００１７】本発明の酪酸菌の液剤は、これを整腸剤と
して用いる場合、その有効投与量は１日１×１０6 個以
上、好ましくは１×１０8 〜１×１０10個であり、投与
方法は１日、１回〜３回、食後に服用することが好まし
いが、適宜、服用することが可能であった。健康食品と
して使用する場合は、その適量を用いる。薬理薬効は、
従来の酪酸菌製剤と全く同じである。When the butyric acid bacterium solution of the present invention is used as an intestinal medicine, the effective dose is 1 × 10 6 or more, preferably 1 × 10 8 to 1 × 10 10 per day. It is preferable to take once to three times a day after meals, but it was possible to take as appropriate. When used as a health food, use the appropriate amount. Pharmacological efficacy
It is exactly the same as the conventional butyric acid bacteria preparation.
【００１８】[0018]
【実施例】 実施例１ （健康ドリンク剤） アップルファイバー粉末 １００ｇ 天然カルシウム粉末 １０ｇ ビタミンＣ １０ｇ 砂糖粉末 ５０ｇ アップル果汁粉末 ５０ｇ アップルフレーバー ３ｍｌ 酪酸菌原菌末 ０．１ｇ アスパラギン ２ｇ 精製水 １０００ｍｌ 以上を混和し、これを塩酸によりpH４．０に調製した。Examples Example 1 (Healthy drink agent) Apple fiber powder 100 g Natural calcium powder 10 g Vitamin C 10 g Sugar powder 50 g Apple juice powder 50 g Apple flavor 3 ml Butyric acid bacterium powder 0.1 g Asparagine 2 g Purified water 1000 ml or more are mixed. This was adjusted to pH 4.0 with hydrochloric acid.
【００１９】 実施例２ （健康ドリンク剤） 白糖 ５０ｇ 安息香酸 ０．６ｇ アラビアゴム １０ｇ 酪酸菌原菌末 ０．１ｇ アスパラギン ２ｇ オレンジ果汁粉末 ５０ｇ 精製水 １０００ｍｌ 以上を混和し、これを塩酸によりpH４．０に調製した。Example 2 (Healthy drink agent) Sucrose 50 g Benzoic acid 0.6 g Arabic gum 10 g Butyric acid bacterium powder 0.1 g Asparagine 2 g Orange juice powder 50 g Purified water 1000 ml or more is mixed, and the mixture is mixed with hydrochloric acid to pH 4.0. Was prepared.
【００２０】[0020]
【発明の効果】本発明によれば、服用が容易な酪酸菌液
剤を提供することができる。According to the present invention, it is possible to provide a butyric acid bacterium solution which is easy to take.
【図１】酪酸菌の生活環を示す図。FIG. 1 shows the life cycle of a butyric acid bacterium.
【図２】各種糖類が発芽に及ぼす影響を示すグラフ。FIG. 2 is a graph showing the effects of various sugars on germination.
フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ｃ１２Ｒ 1:145） (56)参考文献 特開 昭55−160722（ＪＰ，Ａ) (58)調査した分野(Int.Cl.6，ＤＢ名) A61K 35/74 A23L 2/00 - 2/40 A23L 1/29 - 1/305 C12N 1/20Continuation of the front page (51) Int.Cl. 6 identification code FI C12R 1: 145) (56) References JP-A-55-160722 (JP, A) (58) Fields investigated (Int. Cl. 6 , DB Name) A61K 35/74 A23L 2/00-2/40 A23L 1/29-1/305 C12N 1/20
Claims (3)
および／またはアスパラギンを０．１％以上含むことを
特徴とする酪酸菌の液剤。1. A liquid solution of a butyric acid bacterium comprising butyric acid bacterium as a main component and containing 0.1% or more of phenylalanine and / or asparagine.
性に保たれていることを特徴とする請求項１の酪酸菌の
液剤。2. The solution of butyric acid bacterium according to claim 1, wherein butyric acid bacterium is a main component and is kept acidic in a normal state.
・ミヤイリ５８８(Clostridium butyricum MIYAIRI ５
８８）である請求項１又は２の酪酸菌の液剤。3. The butyric acid bacterium is Clostridium butyricum MIYAIRI 5 (Clostridium butyricum MIYAIRI 5).
88. The solution of butyric acid bacterium according to claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3169893A JP2761815B2 (en) | 1991-07-10 | 1991-07-10 | Butyric acid bacteria solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3169893A JP2761815B2 (en) | 1991-07-10 | 1991-07-10 | Butyric acid bacteria solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06166625A JPH06166625A (en) | 1994-06-14 |
| JP2761815B2 true JP2761815B2 (en) | 1998-06-04 |
Family
ID=15894919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3169893A Expired - Fee Related JP2761815B2 (en) | 1991-07-10 | 1991-07-10 | Butyric acid bacteria solution |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2761815B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3920929B2 (en) * | 1997-02-14 | 2007-05-30 | 日宝化学株式会社 | Clostridium butyricum having effects for preventing and treating liver damage, and liver protectant, food and feed comprising the culture |
| JP2013227250A (en) * | 2012-04-25 | 2013-11-07 | Miyarisan Pharmaceutical Co Ltd | Nrf2-ACTIVATING AGENT AND APPLICATION THEREOF |
| CN111328947A (en) * | 2020-04-23 | 2020-06-26 | 广西壮族自治区林业科学研究院 | Preparation method of lilium giganteum carbonated drink |
| CN111647538A (en) * | 2020-06-23 | 2020-09-11 | 科兴生物制药股份有限公司 | Clostridium butyricum freeze-dried powder, preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55160722A (en) * | 1979-05-31 | 1980-12-13 | Kyowa Sangyo Kk | Preparation of drinking water containing aloe extract and live microorganism |
-
1991
- 1991-07-10 JP JP3169893A patent/JP2761815B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06166625A (en) | 1994-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012135499A1 (en) | Probiotic sports nutrition compositions | |
| US20070196341A1 (en) | Preventive and/or remedy for inflammatory bowel diseases | |
| CN102333459A (en) | The composition that comprises caffeoyl tartaric acid and/or its derivative | |
| CN108624523A (en) | Lactobacillus germ TCI378 and its in fat reducing and improve functions of intestines and stomach application | |
| JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
| JP2019528763A (en) | Novel Lactobacillus sakei and composition containing the same | |
| WO1998013068A1 (en) | Medicinal prophylactic 'trisan' | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| JPH04281795A (en) | Production of powder with high content of lactosucrose and use of the same powder | |
| KR101394322B1 (en) | New Bacillus subtilis BCNU 9169 and probiotics composition comprising the same | |
| JPH03151854A (en) | Composition for improving intestinal environment | |
| KR20150092464A (en) | A pharmaceutical composition for treating cognitive and memory impairment | |
| JP2761815B2 (en) | Butyric acid bacteria solution | |
| JP6301024B2 (en) | Felicaribacterium spp. | |
| CN113750113A (en) | Composition of probiotics and prebiotics and application thereof | |
| KR20180125895A (en) | Composition with Lactobacillus sp. KCCM 11826P for preventing, treating or improving disease from uremic toxins | |
| JP3390613B2 (en) | Bifidus factor activity enhancer / stabilizer | |
| JP2008074734A (en) | Ameliorating agent for insulin resistance | |
| JPS63291579A (en) | Proliferation-promoting agent for bifidobacterium | |
| KR20120119555A (en) | COMPOSITION FOR α-GLUCOSIDASE INHIBITORY ACTIVITY | |
| US20200316141A1 (en) | Composition To Support Healthy Brain Function | |
| RU2325166C1 (en) | Pharmaceutical formulation of antibiotics and lactulose applied for prevention of enteral disbiosis caused by antibiotic therapy | |
| KR101376629B1 (en) | New Lactobacillus arizonensis BCNU 9200 and probiotics composition comprising the same | |
| JPH0131487B2 (en) | ||
| GYÖRGY | Nutrition and intestinal flora in man |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090327 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100327 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100327 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110327 Year of fee payment: 13 |
|
| LAPS | Cancellation because of no payment of annual fees |